Last reviewed · How we verify
HD quadrivalent influenza vaccine
HD quadrivalent influenza vaccine stimulates immune responses against four strains of influenza virus using a high-dose antigen formulation to enhance protection, particularly in older adults.
HD quadrivalent influenza vaccine stimulates immune responses against four strains of influenza virus using a high-dose antigen formulation to enhance protection, particularly in older adults. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in adults aged 18 years and older (Phase 3 evaluation).
At a glance
| Generic name | HD quadrivalent influenza vaccine |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains increased amounts of inactivated influenza virus antigens (hemagglutinin) from four circulating influenza strains (two A subtypes and two B lineages) compared to standard-dose vaccines. The higher antigen dose is designed to trigger stronger humoral and cellular immune responses, improving vaccine efficacy and duration of protection especially in elderly populations with waning immune function.
Approved indications
- Prevention of influenza in adults aged 65 years and older
- Prevention of influenza in adults aged 18 years and older (Phase 3 evaluation)
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
- Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: